Physician profile
Tarah Wright
NPI 1710453121
$4,401.83
in general payments reported to CMS, 2019-2025
21 companies · $1,834 in 2025
The $1,834 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $119 · 2023: $267 · 2024: $1,546 · 2025: $1,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $638.01 | 2021-2025 | Qelbree |
| Abbvie INC. | $626.88 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $558.47 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $419.12 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $372.97 | 2024 | |
| Alkermes, INC. | $267.88 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $247.76 | 2023-2025 | Trintellix |
| Lundbeck LLC | $190.48 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $182.55 | 2024-2025 | Invega, Spravato |
| Axsome Therapeutics, INC. | $167.53 | 2024-2025 | Auvelity |
| Corium, LLC | $161.31 | 2023-2025 | Azstarys, Azstarys |
| Biogen, INC. | $105.89 | 2025 | Zurzuvae |
| Neos Therapeutics, Lp | $103.73 | 2024-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $80.54 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| E.R. Squibb & Sons, L.L.C. | $73.35 | 2024-2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $58.78 | 2023-2024 | Hetlioz, Fanapt |
| Vertical Pharmaceuticals, LLC | $51.30 | 2024-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $35.39 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $29.52 | 2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $15.66 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $14.71 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarah Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.